AU2022349649A1 - Adenoviruses and methods for using adenoviruses - Google Patents

Adenoviruses and methods for using adenoviruses Download PDF

Info

Publication number
AU2022349649A1
AU2022349649A1 AU2022349649A AU2022349649A AU2022349649A1 AU 2022349649 A1 AU2022349649 A1 AU 2022349649A1 AU 2022349649 A AU2022349649 A AU 2022349649A AU 2022349649 A AU2022349649 A AU 2022349649A AU 2022349649 A1 AU2022349649 A1 AU 2022349649A1
Authority
AU
Australia
Prior art keywords
seq
polypeptide
amino acid
recombinant
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022349649A
Other languages
English (en)
Inventor
Kayvan Niazi
Shahrooz Rabizadeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sagittarius Bio Inc
Original Assignee
Sagittarius Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sagittarius Bio Inc filed Critical Sagittarius Bio Inc
Publication of AU2022349649A1 publication Critical patent/AU2022349649A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C12N2710/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2022349649A 2021-09-23 2022-09-23 Adenoviruses and methods for using adenoviruses Pending AU2022349649A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163261561P 2021-09-23 2021-09-23
US63/261,561 2021-09-23
PCT/US2022/076951 WO2023049852A1 (en) 2021-09-23 2022-09-23 Adenoviruses and methods for using adenoviruses

Publications (1)

Publication Number Publication Date
AU2022349649A1 true AU2022349649A1 (en) 2024-04-04

Family

ID=85721290

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022349649A Pending AU2022349649A1 (en) 2021-09-23 2022-09-23 Adenoviruses and methods for using adenoviruses

Country Status (7)

Country Link
US (1) US20240398939A1 (https=)
EP (1) EP4404947A4 (https=)
JP (1) JP2024536835A (https=)
CN (1) CN118354779A (https=)
AU (1) AU2022349649A1 (https=)
CA (1) CA3233100A1 (https=)
WO (1) WO2023049852A1 (https=)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2487811A1 (en) 2002-05-27 2003-12-04 Per Sonne Holm Use of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors
US20080063656A1 (en) * 2004-08-09 2008-03-13 Emini Emilio A Adenoviral Vector Compositions
US8926987B2 (en) 2004-11-18 2015-01-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Replication-competent adenoviral vectors
WO2011022002A1 (en) * 2009-08-18 2011-02-24 The Rockefeller University Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
US20120283318A1 (en) 2009-10-05 2012-11-08 Mei Ya-Fang Replicating viral vectors for gene therapy
WO2012088041A1 (en) * 2010-12-20 2012-06-28 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
WO2014093270A1 (en) 2012-12-10 2014-06-19 Virginia Commonwealth University Tropism modified cancer terminator virus (ad.5/3 ctv;ad.5/3-ctv-m7)
AU2014338864C1 (en) 2013-10-25 2020-07-16 Akamis Bio Limited Oncolytic adenoviruses armed with heterologous genes
PE20180241A1 (es) 2015-04-30 2018-01-31 Psioxus Therapeutics Ltd Adenovirus oncolitico que codifica una proteina b7
US11866724B2 (en) * 2016-04-06 2024-01-09 Gene Bridges Gmbh Adenoviral vectors
EP3565578A1 (en) 2016-12-21 2019-11-13 Memgen LLC Armed replication-competent oncolytic adenoviruses
GB201804473D0 (en) 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
CA3120715A1 (en) * 2018-11-21 2020-05-28 Mayo Foundation For Medical Education And Research Adenoviruses and methods for using adenoviruses

Also Published As

Publication number Publication date
CA3233100A1 (en) 2023-03-30
WO2023049852A1 (en) 2023-03-30
US20240398939A1 (en) 2024-12-05
JP2024536835A (ja) 2024-10-08
EP4404947A1 (en) 2024-07-31
CN118354779A (zh) 2024-07-16
EP4404947A4 (en) 2025-12-10

Similar Documents

Publication Publication Date Title
JP7381706B2 (ja) 祖先ウイルス配列を予測する方法およびその使用
KR101761683B1 (ko) 유인원 아과 ｂ 아데노바이러스 ｓａｄｖ-28,27,-29,-32,-33, 및 -35 및 그것의 사용
KR100379569B1 (ko) 개기원의아데노바이러스벡터및유전자치료에서이의사용방법
KR101614369B1 (ko) 유인원 아과 ｃ 아데노바이러스 ｓａｄｖ-40, -31, 및 -34 및 그것의 사용
KR101614364B1 (ko) 유인원 ｅ 아데노바이러스 ｓａｄｖ-39, -25.2, -26, -30, -37, 및 -38
KR20180107105A (ko) 항-tcr-복합체 항체 또는 단편을 암호화하는 군 b 아데노바이러스
JP2011055835A (ja) サルアデノウイルス核酸およびアミノ酸配列、それを含むベクターおよび使用方法
KR20130138245A (ko) 종양분해 아데노바이러스 벡터 및 이와 관련된 방법 및 용도
JP2001508304A (ja) 細胞内及び細胞間輸送のための融合タンパク質、並びにその使用
WO1998035028A9 (en) An oncolytic/immunogenic complementary-adenoviral vector system
CN121320270A (zh) 表达car t细胞靶物的溶瘤病毒及其用途
KR20160102024A (ko) 아데노바이러스 및 상응하는 플라스미드의 제조 방법
JP5148116B2 (ja) 癌胎児性抗原融合タンパク質及びその使用
RU2756534C2 (ru) Композиции и способы для повышения стабильности трансгенов в поксвирусах
KR20230153405A (ko) Il-15를 암호화하는 아데노바이러스
CN115427071A (zh) 包含ltb和病原性抗原的组合物及其用途
JP2002511751A (ja) スプライシング配列を含んでなる組換えアデノウイルスベクター
US20070104685A1 (en) Synthetic gene encoding human carcinoembryonic antigen and uses thereof
US20240398939A1 (en) Adenoviruses and methods for using adenoviruses
JP2006502726A (ja) 改善された免疫療法
CN114317606A (zh) 靶向人nk细胞的腺病毒载体及其应用
EP1489164A1 (en) Recombinant vaccinia viruses with modified F3 genes, uses thereof
US20060286114A1 (en) Synthetic gene encoding rhesus monkey carcinoembryonic antigen and uses thereof
NZ783284A (en) Modified adenoviruses
NZ783284B2 (en) Modified adenoviruses